Clinical trials: Community-acquired Bacterial Pneumonia
Community Acquired Pneumonia
Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP
The purpose of this study is to determine whether the adjunctive therapy to standard antibiotic treatment of BT086 is safe and effective of decreasing the days patients require endotracheal ventilation due to Severe…
- Trial name
- CIGMA (NCT01420744)
- Testing
- BT086, 1% Human Albumin infusion
- Where
- 36 sites in Belgium, Germany and 2 more
- Volunteers
- 160 people
- Sponsor
- Biotest
Community-Acquired Pneumonia (CAP)
Lefamulin Post-Market Surveillance Study
Community-acquired pneumonia (CAP) refers to infectious parenchymal lung inflammation acquired outside hospital settings. In China, its incidence is 7.13 per 1000 person-years, with over 10 million new cases annually.
- Trial name
- NCT07697885
- Testing
- This is a multicenter, single-arm, non-interventional study. No interventional measures will be adopted.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Pneumonia, Bacterial
Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia
To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to Streptococcus pneumoniae.
- Trial name
- NCT00538694
- Testing
- daptomycin
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pneumonia
A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
The main objective of this study is to investigate the safety, pharmacokinetics (PK) and the relationship between PK and pharmacodynamics (Minimum Inhibitory Concentration [MIC] and Mutant Prevention Concentration [MPC]) of…
- Trial name
- NCT01561794
- Testing
- Ciprofloxacin (Cipro, BAYQ3939)
- Where
- 20 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Bayer
Bacterial Pneumonia, Community-Acquired Infections
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
- Trial name
- NCT02531438
- Testing
- Omadacycline, Moxifloxacin
- Where
- 140 sites in United States, Belgium and 23 more
- Volunteers
- 774 people
- Sponsor
- Paratek Pharmaceuticals Inc
Community-acquired Pneumonia
Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia
The purpose of this study is to evaluate the pharmacokinetics of an oral omadacycline dosing regimen in the treatment of adults with CABP.
- Trial name
- NCT04160260
- Testing
- Omadacycline
- Where
- 13 sites in United States
- Volunteers
- 18 people
- Sponsor
- Paratek Pharmaceuticals Inc
Infections, Bacterial
A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS
The purpose of this study is to evaluate the pharmacokinetics, safety or tolerability through treatment emergent adverse event (TEAE) and to explore primary and secondary clinical response of treatment with Augmentin ES in…
- Trial name
- NCT05340257
- Testing
- Augmentin ES
- Where
- 2 sites in Brazil
- Sponsor
- GlaxoSmithKline
Community-acquired Pneumonia
Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
The goal of this clinical trial is to compare the safety and efficacy of AON-D21 versus placebo, both on top of standard of care, in patients with severe community acquired pneumonia admitted to ICU (or similar unit).
- Trial name
- NCT05962606
- Testing
- AON-D21
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 150 people
- Sponsor
- Aptarion Biotech AG
Infections, Community Acquired Pneumonia
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)
This is a study of safety and effectiveness of ceftaroline fosamil in children with Community Acquired Bacterial Pneumonia receiving antibiotic therapy in the hospital.
- Trial name
- NCT01530763
- Testing
- Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate
- Where
- 44 sites in United States, Argentina and 7 more
- Volunteers
- 161 people
- Sponsor
- Forest Laboratories
Pneumonia, Pneumococcal Infections
Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae
The objectives of this study are to assess the safety, tolerability, clinical and microbiological efficacy and pharmacodynamics of patients who have severe pneumonia caused by Streptococcus pneumoniae after the intravenous…
- Trial name
- NCT02583373
- Testing
- CAL02 Low-dose, CAL02 High-dose
- Where
- 10 sites in Belgium, France
- Volunteers
- 19 people
- Sponsor
- Combioxin SA
Infections, Streptococcal
COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine
This is a study in a large number of healthy children less than 3 years old to measure the efficacy of GlaxoSmithKline (GSK) Biologicals' 10-valent pneumococcal conjugate candidate vaccine (Synflorix vaccine, or GSK1024850A) to…
- Trial name
- NCT00466947
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Havrix, Engerix-B
- Where
- 22 sites in Argentina, Colombia and 1 more
- Volunteers
- 23,802 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
The main purpose of this study is to compare the safety of tigecycline versus a ceftriaxone regimen in pediatric subjects (aged 8 to 17 years) with complicated intra-abdominal infections (cIAI) and community acquired pneumonia…
- Trial name
- NCT01602874
- Testing
- Tigecycline, cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside, CAP: Ceftriaxone, plus if applicable oral clarithromycin
- Sponsor
- Pfizer
Community-acquired Bacterial Pneumonia
Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
This study will evaluate the safety and efficacy of an experimental antibiotic, solithromycin, in the treatment of adult patients with community-acquired pneumonia.
- Trial name
- SOLITAIRE-IV (NCT01968733)
- Testing
- Solithromycin, Moxifloxacin
- Where
- 270 sites in United States, Argentina and 24 more
- Volunteers
- 863 people
- Sponsor
- Melinta Therapeutics, Inc.
Community Acquired Pneumonia
A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia
The purpose of this study is to evaluate the safety and Efficacy of Faropenem in community-acquired pneumonia (CAP) subjects，and explore its therapeutic dose.
- Trial name
- NCT01886053
- Testing
- Faropenem（high dose group）, Faropenem（low-dose group), Ertapenem
- Where
- 9 sites in China
- Volunteers
- 189 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pneumonia, Bacterial
Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae
A COMPARASON OF CIDECIN™ (DAPTOMYCIN) TO ROCEPHIN® (CEFTRIAXONE) IN THE TREATMENT OF MODERATE TO SEVERE COMMUNITY-ACQUIRED ACUTE BACTERIAL PNEUMONIA DUE TO S. PNEUMONIAE
- Trial name
- NCT00540072
- Testing
- daptomycin
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)